Skip to content

Clinical study of remazolam mesylate in hysteroscopic surgery

Clinical study of remazolam mesylate in hysteroscopic surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041439
Enrollment
Unknown
Registered
2020-12-26
Start date
2021-01-30
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pain

Interventions

Sponsors

Yantai Affiliated Hospital of Binzhou Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. ASA I or II patients; 2. Patients aged 18-60 years old; 3. Patients with body weight of 45-85kg and BMI of 18.5-24kg/m2; 4. Patients undergoing hysteroscopy or hysteroscopic surgery; 5. Patients with clear consciousness and active cooperation can understand the postoperative recovery quality assessment scale, qor-40 emotional scale and so on after a short training.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to propofol or to rimazole; 2. Patients with severe cardiac dysfunction; 3. Patients with respiratory tract management difficulties (modified Mahalanobis score is grade IV); 4. Patients with chronic respiratory insufficiency; 5. Patients with severe abnormal liver and kidney function (alanine aminotransferase 3 times higher than normal or creatinine higher than normal); 6. Patients with central nervous system or psychological diseases, history of chronic pain, long-term use of sedatives and antidepressants before operation, alcoholism, drug dependence, etc.

Design outcomes

Primary

MeasureTime frame
haemodynamics;The number of cases of limb movement that need to be dealt with during the operation;hypotension;respiratory depression;

Countries

China

Contacts

Public ContactJia Shushan

Yantai Affiliated Hospital of Binzhou Medical College

jiashushan@163.com+86 13306499099

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026